Oncocross Co.,Ltd. Logo

Oncocross Co.,Ltd.

AI-powered biotech accelerating drug development for cancer and rare diseases.

382150 | KO

Overview

Corporate Details

ISIN(s):
KR7382150001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로11길 7 905호(문정동, 문정현대지식산업센터1-2), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oncocross Co., Ltd. is an AI-powered biotechnology company focused on innovating the drug development process. The company leverages its proprietary AI platforms, such as RAPTOR AI™, to analyze an extensive, medically curated transcriptome database of patient, drug, and disease gene expression data. This technology-driven approach enables the identification of optimal drug-disease indications, facilitates drug repositioning to discover new therapeutic uses, and aims to reduce the time, cost, and failure rates of clinical trials. Oncocross concentrates on developing treatments for intractable conditions, including cancers and rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제1회차 CB)
Korean 5.6 KB
2025-07-22 00:00
Share Issue/Capital Change
기타경영사항(자율공시) (상장주관사의 신주인수권행사)
Korean 8.7 KB
2025-07-21 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 77.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.0 MB
2025-04-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 355.0 KB
2025-04-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 30.5 KB
2025-04-15 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.9 KB
2025-04-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 366.6 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.0 KB
2025-03-28 00:00
Board/Management Information
대표이사변경
Korean 10.9 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.3 KB
2025-03-20 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 457.5 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.1 KB

Automate Your Workflow. Get a real-time feed of all Oncocross Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncocross Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncocross Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Atomera Inc Logo
Licenses semiconductor material and IP to enhance transistor performance and power efficiency.
United States of America
ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan
6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia
AEE
Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing IL-1β therapies for immune inflammatory diseases.
United States of America
AVTX
AVIS BUDGET GROUP, INC. Logo
Global provider of car rental, truck rental, and car-sharing for business & leisure travelers.
United States of America
CAR
Azenta, Inc. Logo
Life science solutions for pharma & biotech, offering sample management, storage & multiomics.
United States of America
AZTA
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan
6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom
BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway
BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden
BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.